STOCK TITAN

Glucotrack - GCTK STOCK NEWS

Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.

Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.

Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.

Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.

Rhea-AI Summary

Glucotrack (Nasdaq: GCTK) has appointed Ted Williams as Vice President of Regulatory Affairs, effective immediately. Williams brings nearly 25 years of experience in regulatory affairs and quality assurance for Class III medical devices, including expertise in continuous glucose monitors (CGM) and drug/device combination products.

Williams previously served as Vice President of Regulatory Affairs/Quality Assurance at Glysens Inc, focusing on implantable CGM development. His experience spans roles at Therapeutics Inc. and Cardium Therapeutics, working with various medical technologies.

The appointment aims to advance Glucotrack's human clinical trials and regulatory program for their Continuous Blood Glucose Monitor (CBGM). According to CEO Paul V. Goode, Williams' expertise will be important in navigating FDA pathways as they develop their CBGM technology for diabetes patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.25%
Tags
management
-
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes care technologies, has announced its participation in the upcoming TechBio Showcase™ 2025. The company's President and CEO, Paul V. Goode, will deliver a corporate update focusing on their Continuous Blood Glucose Monitor (CBGM) technology.

The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite C track. TechBio Showcase, part of Biotech Showcase™ 2025, is organized by Demy-Colton and EBD Group. This investor conference serves as a networking platform for executives and investors, promoting geographical investment and partnership opportunities in therapeutic development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
conferences
-
Rhea-AI Summary

Glucotrack (NASDAQ: GCTK) has initiated patient enrollment for a short-term human clinical study of its continuous blood glucose monitor (CBGM). The study includes both type 1 and type 2 diabetes patients, with results expected in 6-8 weeks. The CBGM is a long-term implantable device that measures glucose directly from blood, designed to work for three years without external components. The four-day in-hospital study is being conducted at Instituto do Coração under Dr. Alexandre Abizaid, involving intravascular sensor placement and fixed meal challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK) has completed a $10.0 million public offering and concurrent private placement. The offering included 2,437,340 shares of common stock and 4,756,900 pre-funded warrants at $1.39 per share. Each share and warrant came with series A and B common warrants exercisable at $1.81 per share. Additionally, the company converted $4.0 million in outstanding secured convertible notes from July 2024 into equity on similar terms. Dawson James Securities acted as the sole placement agent for the public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.06%
Tags
private placement offering
-
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK) announced a $10.0 million public offering of approximately 7,195,000 shares of common stock or pre-funded warrants at $1.39 per unit. Each unit includes series A and B common warrants exercisable at $1.81 per share. Additionally, the company will convert approximately $4.0 million in outstanding secured convertible notes from July 2024 in a concurrent private placement. The offering is expected to close on November 14, 2024, with Dawson James Securities acting as the sole placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-77.06%
Tags
-
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK), a medical technology company focusing on diabetes technologies, will participate in the 2024 BioFuture Conference in New York City from October 28-30, 2024. Paul V. Goode, President & CEO, will present on October 29 at 11:00 AM ET, providing an update on the company's continuous blood glucose monitor (CBGM) development.

The BioFuture Conference will explore topics such as quantum computing in biology, alternative financing, AI in healthcare, psychedelics in mental health treatments, and bioethical challenges. Speakers from prominent companies like Regeneron Pharmaceuticals, IBM, and JP Morgan will discuss major trends shaping healthcare's future.

Qualified investors and media can apply for complimentary registration to attend the conference, which will feature over 100 future-focused presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
Rhea-AI Summary

Glucotrack, Inc. (Nasdaq: GCTK) announced that updated preclinical data for its continuous blood glucose monitor (CBGM) will be presented at the 24th Annual Diabetes Technology Meeting from October 15-17, 2024, in Burlingame, California. Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver an oral presentation titled "The Technology Behind Continuous Blood Glucose Monitoring" on October 17.

The company will also present two posters: "In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model" and "Exploratory Study of Continuous Glucose Monitoring in the Epidural Space in Swine". These presentations aim to showcase the CBGM's ability to accurately measure glucose levels without the lag time associated with interstitial glucose and without an on-body wearable, potentially offering a less intrusive approach for people with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
none
-
Rhea-AI Summary

Glucotrack Inc. (Nasdaq: GCTK), a medical technology company focused on developing novel technologies for diabetes management, has appointed John Ballantyne, PhD, to its Board of Directors. Ballantyne brings over 20 years of experience from Aldevron, a global biotechnology contract development and manufacturing organization he co-founded. As former Chief Science Officer at Aldevron, Ballantyne has extensive experience in healthcare research, innovation, and strategic growth.

Paul Goode, PhD, President and CEO of Glucotrack, expressed confidence that Ballantyne's expertise will be invaluable as the company expands and moves towards commercializing its novel continuous blood glucose monitoring (CBGM) technology. Ballantyne, who holds a Doctorate in Pharmaceutical Sciences, has developed relationships across various biotechnology sectors through investments and advisory roles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
management
-
Rhea-AI Summary

Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on diabetes management, has announced the appointment of Sandie Martha as Vice President of Clinical Operations. With over 20 years of experience in clinical research, Martha brings expertise in leading global clinical trials for glucose monitoring and cardiology. Her role will be important in executing Glucotrack's Clinical Trial Program for their Continuous Blood Glucose Monitor (CBGM).

Martha's extensive background includes leadership positions at Glysens, Dexcom, and Truvian, where she managed various aspects of clinical trials and regulatory submissions. Her appointment is seen as a strategic move to advance Glucotrack's CBGM technology through clinical trials and ultimately bring it to market for millions of people living with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
Rhea-AI Summary

Glucotrack Inc. (Nasdaq: GCTK) presented new findings at the ADCES 2024 Annual Conference, revealing strong interest in their innovative Continuous Blood Glucose Monitor (CBGM) concept. The market research study showed that over 50% of surveyed diabetes patients are open to adopting this new technology.

Key features attracting interest include:

  • Long-term sensor life (up to 3 years)
  • No wearable component
  • Real-time blood glucose readings

The study included 757 respondents with intensive insulin therapy, comprising current CGM users (67%), non-users (25%), and ex-users (8%). Glucotrack's CBGM concept aims to address unmet needs in diabetes management, offering a more convenient and less intrusive monitoring solution. The company has made significant clinical progress, completing successful preclinical studies and planning to initiate human clinical trials later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.7%
Tags
none
Glucotrack

Nasdaq:GCTK

GCTK Rankings

GCTK Stock Data

2.09M
22.58M
2.34%
0.43%
7.56%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD